Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 12/20 | 0.63 |
| ▸ | ADRA2A | P08913 | 7/20 | 0.63 |
| ▸ | ADRA2B | P18089 | 3/20 | 0.63 |
| ▸ | ADRA2C | P18825 | 3/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6391507 | 1.00 | PNMT (0.63) | PNMTADRA2AADRA2BADRA2C | |
| SCHEMBL1491480 | 1.00 | PNMT (0.63) | PNMTADRA2AADRA2BADRA2C | |
| SCHEMBL11167697 | 1.00 | PNMT (0.63) | PNMTADRA2AADRA2BADRA2C | |
| Hydrochloric Acid SCHEMBL8488582 | 0.99 | PNMT (0.62) | PNMTADRA2AADRA2BADRA2C | |
| Hydrochloric Acid SCHEMBL28292450 | 0.99 | PNMT (0.62) | PNMTADRA2AADRA2BADRA2C | |
| SCHEMBL15623045 | 0.94 | PNMT (0.56) | PNMTADRA2AADRA2BADRA2C | |
| SCHEMBL6921990 | 0.84 | PNMT (0.61) | PNMTADRA2AADRA2BADRA2C | |
| SCHEMBL1202143 | 0.84 | PNMT (0.61) | PNMTADRA2AADRA2BADRA2C | |
| Hydrochloric Acid SCHEMBL6398473 | 0.83 | PNMT (0.60) | PNMTADRA2AADRA2BADRA2C | |
| Hydrochloric Acid SCHEMBL2081344 | 0.83 | PNMT (0.60) | PNMTADRA2AADRA2BADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050154011-A1 | Tetrahydroisoquinolnyl sulfamic acids | THE PROCTER & GAMBLE COMPANY | 2005-07-14 | — | — | US | claimed |
| WO-2004074256-A1 | TETRAHYDROISOQUINOLINYL SULFAMIC ACIDS | THE PROCTER & GAMBLE COMPANY (US) | 2004-09-02 | — | — | WO | claimed |
| EP-3313854-A1 | MACROCYCLIC BENZODIAZEPINE DIMERS, CONJUGATES THEREOF, PREPARATION AND USES | Bristol-Myers Squibb Company (US) | 2018-05-02 | — | — | EP | disclosed |
| US-9902740-B2 | Macrocyclic benzodiazepine dimers, conjugates thereof, preparation and uses | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-02-27 | — | — | US | disclosed |
| EP-2897949-B1 | IAP ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2018-01-10 | — | — | EP | disclosed |
| US-9783573-B2 | IAP antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-10-10 | — | — | US | disclosed |
| US-20170260205-A1 | MACROCYCLIC BENZODIAZEPINE DIMERS, CONJUGATES THEREOF, PREPARATION AND USES | BRISTOL-MYERS SQUIBB COMPANY | 2017-09-14 | — | — | US | disclosed |
| US-9688694-B2 | Macrocyclic benzodiazepine dimers, conjugates thereof, preparation and uses | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-06-27 | — | — | US | disclosed |
| WO-2016209951-A1 | MACROCYCLIC BENZODIAZEPINE DIMERS, CONJUGATES THEREOF, PREPARATION AND USES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-12-29 | — | — | WO | disclosed |
| US-20160376288-A1 | MACROCYCLIC BENZODIAZEPINE DIMERS, CONJUGATES THEREOF, PREPARATION AND USES | BRISTOL-MYERS SQUIBB COMPANY | 2016-12-29 | — | — | US | disclosed |
| US-20150322111-A1 | IAP ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY | 2015-11-12 | — | — | US | disclosed |
| EP-1835934-A2 | ENZYME MODULATORS AND TREATMENTS | Deciphera Pharmaceuticals, LLC (US) | 2007-09-26 | — | — | EP | disclosed |
| US-20070078121-A1 | Enzyme modulators and treatments | DECIPHERA PHARMACEUTICALS, LLC | 2007-04-05 | — | — | US | disclosed |
| WO-2006117549-A1 | ENZYME INHIBITORS | CHROMA THERAPEUTICS LTD (GB) | 2006-11-09 | — | — | WO | disclosed |
| WO-2006071940-A2 | ENZYME MODULATORS AND TREATMENTS | DECIPHERA PHARMACEUTICALS, LLC (US) | 2006-07-06 | — | — | WO | disclosed |
| US-20050154011-A1 | Tetrahydroisoquinolnyl sulfamic acids | THE PROCTER & GAMBLE COMPANY | 2005-07-14 | — | — | US | disclosed |
| WO-2004074256-A1 | TETRAHYDROISOQUINOLINYL SULFAMIC ACIDS | THE PROCTER & GAMBLE COMPANY (US) | 2004-09-02 | — | — | WO | disclosed |
| EP-0088350-B1 | CARBOXYALKYL DIPEPTIDES, PROCESSES FOR THEIR PRODUCTION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SCHERING CORPORATION (US) | 1985-02-20 | — | — | EP | disclosed |
| EP-0018104-B1 | TETRAHYDROISOQUINOLINES, THEIR PRODUCTION AND THE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM FOR USE IN THE PREVENTION OR TREATMENT OF HYPERTENSION | Takeda Chemical Industries, Ltd. (JP) | 1983-05-25 | — | — | EP | disclosed |
| EP-0018104-A2 | Tetrahydroisoquinolines, their production and the compounds and pharmaceutical compositions containing them for use in the prevention or treatment of hypertension | Takeda Chemical Industries, Ltd. (JP) | 1980-10-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150322111-A1 | IAP ANTAGONISTS | XIAP, BIRC5, API5 | PNMT 4466/4885ADRA2A 2831/4885ADRA2B 2735/4885 |
| US-20050154011-A1 | Tetrahydroisoquinolnyl sulfamic acids | PTPRS, PTPRJ, PTPRM | PNMT 1903/4885ADRA2A 4685/4885ADRA2B 4699/4885 |
| US-20170260205-A1 | MACROCYCLIC BENZODIAZEPINE DIMERS, CONJUGATES THEREOF, PREPARATION AND USES | GABRA1, GABRA2, GABRA3 | PNMT 2204/4885ADRA2A 204/4885ADRA2B 107/4885 |
| US-20070078121-A1 | Enzyme modulators and treatments | ABL1, ABL2, LCK | PNMT 998/4885ADRA2A 2388/4885ADRA2B 2647/4885 |
| US-20160376288-A1 | MACROCYCLIC BENZODIAZEPINE DIMERS, CONJUGATES THEREOF, PREPARATION AND USES | GABRA1, GABRA2, GABRA3 | PNMT 2204/4885ADRA2A 204/4885ADRA2B 107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.